Zenas Biopharma

Forecast & Rating8 analysts currently cover Zenas Biopharma, with about 87.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $47.00, about 49.2% upside from the current price of $31.50. Price targets range from $32.00 to $59.00 — a wide spread, showing clear disagreement over just how much Zenas Biopharma can rise. Historically, about 82.0% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Zenas Biopharma closely still see room for the stock to rise. Data as of Sep 9, 2026; for reference only and not investment advice.